GlassScriptPhysician profile
Odeth Barrett-Campbell
NPI 1306297999
$3,075.76
in general payments reported to CMS, 2019-2025
39 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $312 · 2023: $529 · 2024: $1,378 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,341 · Education: $423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,341.23 |
| Education | $422.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $257.16 | 2023-2025 | Padcev, Vyloy, Xtandi |
| Janssen Biotech, INC. | $225.96 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Novartis Pharmaceuticals Corporation | $212.13 | 2022-2025 | |
| Incyte Corporation | $207.58 | 2022-2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $198.72 | 2022-2025 | Opdivo, Opdualag, Eliquis |
| Abbvie INC. | $196.71 | 2024-2025 | |
| Daiichi Sankyo INC. | $189.49 | 2024-2025 | Injectafer, Enhertu, Datroway |
| Seagen INC. | $177.95 | 2022-2025 | Adcetris |
| Pfizer INC. | $163.11 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $143.59 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Celgene Corporation | $138.39 | 2022-2024 | Opdualag, Pomalyst, Reblozyl |
| Glaxosmithkline, LLC. | $111.00 | 2023-2025 | Zejula, Ojjaara, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $98.45 | 2023-2025 | |
| Stemline Therapeutics INC. | $83.92 | 2024-2025 | Orserdu, Elzonris |
| Array Biopharma INC | $65.81 | 2024-2025 | Xalkori, Braftovi, Mektovi |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Odeth Barrett-Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.